Endologix, Inc. (NASDAQ:ELGX) – Analysts at Leerink Swann reduced their FY2017 EPS estimates for Endologix in a note issued to investors on Wednesday. Leerink Swann analyst R. Misra now anticipates that the medical instruments supplier will post earnings of ($0.61) per share for the year, down from their previous estimate of ($0.60). Leerink Swann also issued estimates for Endologix’s Q4 2017 earnings at ($0.22) EPS, FY2018 earnings at ($0.52) EPS, FY2019 earnings at ($0.46) EPS and FY2020 earnings at ($0.32) EPS.
Other research analysts also recently issued reports about the stock. Canaccord Genuity reaffirmed a “hold” rating on shares of Endologix in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. set a $5.00 target price on shares of Endologix and gave the company a “hold” rating in a research report on Thursday, August 3rd. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the company a “hold” rating in a research report on Wednesday, August 2nd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $5.00 target price on shares of Endologix in a research report on Monday, July 31st. Finally, Zacks Investment Research downgraded shares of Endologix from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating and eleven have issued a hold rating to the stock. Endologix currently has an average rating of “Hold” and a consensus target price of $6.13.
ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Endologix, Inc. (ELGX) Cut by Analyst” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/12/fy2017-eps-estimates-for-endologix-inc-elgx-cut-by-analyst.html.
Endologix (ELGX) opened at $5.06 on Friday. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.12 and a current ratio of 2.90. Endologix has a 52-week low of $4.08 and a 52-week high of $10.36.
A number of institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its position in Endologix by 0.4% during the 2nd quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock worth $465,000 after purchasing an additional 381 shares during the last quarter. Kopp Investment Advisors LLC lifted its stake in shares of Endologix by 11.5% in the 2nd quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after acquiring an additional 2,270 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Endologix by 4.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 66,890 shares of the medical instruments supplier’s stock worth $325,000 after acquiring an additional 2,738 shares during the period. American International Group Inc. lifted its stake in shares of Endologix by 7.1% in the 1st quarter. American International Group Inc. now owns 49,906 shares of the medical instruments supplier’s stock worth $361,000 after acquiring an additional 3,290 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Endologix by 6.9% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 62,065 shares of the medical instruments supplier’s stock worth $449,000 after acquiring an additional 3,980 shares during the period.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.